Antibodies
17 January 2014
Takeda Announces the New Drug Application Approval of ADCETRIS (brentuximab vedotin) in Japan for the Treatment of Malignant Lymphoma14 January 2014
Genmab Announces DuoBody Platform Collaboration With Lilly14 January 2014
Regeneron and Bayer to Develop New Treatment Option for Wet Age-Related Macular Degeneration13 January 2014
Zebra Biologics Launched to Commercialize Ground-Breaking Next Gen Platform Technology for Deriving Human Therapeutic Antibodies13 January 2014
Lilly Announces Acquisition of CGRP Antibody for Migraine Prevention from Arteaus Therapeutics13 January 2014
arGEN-X Starts Phase Ib Expansion Cohorts With ARGX-110, a Novel Anti-CD70 Antibody, in Cancer Patients10 January 2014
Immunomedics Announces Initiation of Phase III Clinical Trial of Clivatuzumab Tetraxetan in Patients With Pancreatic Cancer9 January 2014
Mersana Therapeutics Earns Second Milestone Payment in Fleximer-ADC Collaboration with Endo Pharmaceuticals8 January 2014
Labrys Biologics Initiates Two Phase 2 Studies of LBR-101 for the Prevention of Chronic and Episodic Migraine8 January 2014
EPIRUS and Ranbaxy Announce Signing of BOW015 Licensing Partnership For Broad Range of Territories8 January 2014
Immunocore and MedImmune enter immunotherapy agreement to develop novel cancer therapies23 December 2013
Santarus Initiates Phase IIa Study with SAN-300 in Patients with Active Rheumatoid Arthritis23 December 2013
European Commission Approves Update of Erbitux Metastatic Colorectal Cancer Labeling to Patients With RAS Wild-Type Tumors20 December 2013
Roche’s new subcutaneous formulation of RoACTEMRA gains CHMP positive opinion in Europe for moderate to severe rheumatoid arthritis20 December 2013
FibroGen Announces Patient Enrollment in New Phase 2 Clinical Study of FG-3019 for the Treatment of Idiopathic Pulmonary Fibrosis19 December 2013
Amgen Announces Positive Top-Line Results From 52-Week Phase 3 DESCARTES Study Of Evolocumab (AMG 145) In Patients With High Cholesterol19 December 2013
Sandoz begins Phase III clinical trial for biosimilar adalimumabNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports